Terumo Corp Stock Price, News & Analysis

Terumo Cardiovascular announced that the U.S. FDA has granted 510(k) clearance for its CDI OneView Monitoring System. This next-generation platform can measure and display up to 22 key patient parameters during cardiopulmonary bypass surgery, enhancing perfusion safety and patient outcomes. Key new parameters include measured flow (Q), cardiac index (CI), and regional cerebral oxygen saturation (rSO2). The system's modular design allows for flexible configuration to meet clinical needs. Terumo emphasized the system's development was influenced by extensive feedback from global cardiovascular experts and is aimed at reducing complications such as acute kidney injury.

Terumo Blood and Cell Technologies (Terumo BCT) received FDA clearance for the Rika Plasma Donation System with the iNomi Nomogram, a new innovation that allows plasma donors to donate the right amount of plasma based on their individual characteristics. This system aims to increase collection volume without extending collection time, with an average 10% increase in plasma volume collected per donation in less than 35 minutes. Rika is designed for donor comfort and safety, ensuring a seamless and efficient experience for plasma donors and collection center employees. This innovation is expected to enhance patient access to care and support the needs of patients relying on plasma-derived therapies.

Terumo Medical Corporation announced the final results of its R.A.V.I. study, highlighting the safety and efficacy of radial artery access in embolization procedures for conditions such as uterine fibroids and hypervascular tumors. The study, involving 99 patients across six hospitals, demonstrated a 100% procedural success rate with significant patient benefits, including same-day discharge for 74.7% of participants. Presenting the findings at the SIR 2023 Annual Scientific Meeting, Dr. Guimaraes emphasized the potential of radial access to become the preferred method in various embolization procedures. Terumo continues to innovate in interventional techniques.

Terumo Blood and Cell Technologies has received FDA clearance for its IMUGARD® WB Platelet Pooling Set, which extends the shelf life of whole blood-derived platelets from five days to seven days. This innovation aims to address the increasing demand for platelets amid a declining supply due to the shortage of blood donors. In the U.S., over 2.5 million units of platelets were transfused in 2021. The IMUGARD system provides an alternative source for blood centers to manage platelet supply effectively and reduce waste, benefitting patients in need of transfusions.

On November 1, 2022, a study published in JAMA showcased that Terumo Health Outcomes' ePRISM software effectively reduced the risk of acute kidney injury (AKI) in high-risk patients undergoing percutaneous coronary interventions. The three-year randomized study involved 31 cardiologists and 7,106 patients, revealing that AKI rates dropped significantly from 51.7% to 38.1% when using ePRISM. The platform’s personalized contrast volume guidelines not only enhance patient care but could also lead to improved hospital performance metrics and reduced healthcare costs.

MicroVention, a subsidiary of Terumo Corporation, has announced the enrollment of its first patient in the STRAIT observational study. This study will assess the BOBBY Balloon Guide Catheter for treating acute ischemic stroke. The BOBBY device, already approved in Europe and North America, aims to enhance balloon preparation and navigability. The first enrollment took place under the guidance of Dr. Tobias Boeckh-Behrens at a Munich facility, where the device was successfully used in a severe stroke case. The trial will provide clinical evidence for BOBBY's effectiveness in improving outcomes.